Healthcare Industry News: Inflammatory Bowel Disease
News Release - March 27, 2007
Corum Medical Signs Licensing Agreement with Brown University and Rhode Island HospitalProvidence, RI, March 27, 2007 --(HSMN NewsFeed)--Corum Medical, Inc., a medical device startup based in Sudbury, MA and Providence, RI, reports that it has signed a license agreement with Brown University and Rhode Island Hospital. This agreement gives Corum Medical the exclusive worldwide rights for the unique optical spectroscopy technology for the non-invasive hemoglobin measurement.
Hemoglobin, an oxygen transporting protein in the blood stream, is the primary indicator of anemia and is widely used by physicians as one of the vital signs in patient diagnosis and monitoring. The most frequent causes of anemia include malnutrition, parasitic infections, internal hemorrhages and hereditary blood disorders; however, anemia appears also in patients with chronic kidney disease (CKD), cancer, diabetes, malaria, cardiovascular disease, HIV/AIDS, rheumatoid arthritis, and Inflammatory Bowel Disease. Current methods of hemoglobin measurement are based on a blood sample using either a blood draw or a finger stick. These methods are invasive and involve both cost and time delay.
Corum Medical introduces an entirely new approach with a small hand-held device providing a non-invasive hemoglobin value in seconds. This economical point-of-care method will have a significant impact on the efficiency of patient diagnosis and monitoring and quality of patient care in a variety of settings ranging from a doctor’s office to the hospital to home care, says Alan R. Kivnik, CEO and President of Corum Medical.
Source: Corum Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.